FDA approves the first vaccine to prevent meningococcal disease in infants and toddlers
MedSun: Newsletter #61, June 2011
FDA News Release
The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). Neisseria meningitidis is a leading cause of meningitis in young children. Menactra was originally approved in 2005, for use in individuals ages 11 years through 55 years and was approved in October 2007 for children as young as 2 years.
FDA approves the first vaccine to prevent meningococcal disease in infants and toddlers. FDA News Release. April 22, 2011.